Skip Nav Destination
Issues
1 May 2015
-
Cover Image
Cover Image
The newly generated Newcastle disease virus rNDV-B1/Fas encodes the human TNF receptor Fas. Human and murine cancer cells infected by rNDV-B1/Fas displayed a modified cell death response compared with the wild-type rNDV-B1, characterized by an earlier and enhanced apoptosis response due to the overexpression of Fas following the coactivation of both extrinsic and intrinsic apoptosis pathways. The enhanced cytotoxicity shown in vitro correlated with an improved oncolytic activity and therapeutic effect of rNDV-B1/Fas virus in intratumoral-treated melanoma-bearing mice. The cover image shows murine B16-F10 melanoma cells infected by rNDV-B1/Fas virus. The human Fas receptor (red) is expressed on the surface of infected cells (green) but also internalized following induction of apoptosis. DNA was counterstained with Hoechst. For details, see the article by Cuadrado-Castano and colleagues on page 1247. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity
Archana Jalota-Badhwar; Dimple R. Bhatia; Srinivas Boreddy; Asavari Joshi; Magesh Venkatraman; Nikesh Desai; Sarika Chaudhari; Julie Bose; Lakshmi S. Kolla; Vijaykumar Deore; Nilambari Yewalkar; Sanjay Kumar; Rajiv Sharma; Anagha Damre; Avinash More; Somesh Sharma; Veena R. Agarwal
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
John J. Tentler; Anastasia A. Ionkina; Aik Choon Tan; Timothy P. Newton; Todd M. Pitts; Magdalena J. Glogowska; Peter Kabos; Carol A. Sartorius; Kelly D. Sullivan; Joaquin M. Espinosa; S. Gail Eckhardt; Jennifer R. Diamond
Large Molecule Therapeutics
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Edward B. Reilly; Andrew C. Phillips; Fritz G. Buchanan; Gillian Kingsbury; Yumin Zhang; Jonathan A. Meulbroek; Todd B. Cole; Peter J. DeVries; Hugh D. Falls; Christine Beam; Jinming Gu; Enrico L. Digiammarino; Joann P. Palma; Cherrie K. Donawho; Neal C. Goodwin; Andrew M. Scott
Cancer Biology and Signal Transduction
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Lisa Christiansson; Stina Söderlund; Sara Mangsbo; Henrik Hjorth-Hansen; Martin Höglund; Berit Markevärn; Johan Richter; Leif Stenke; Satu Mustjoki; Angelica Loskog; Ulla Olsson-Strömberg
Companion Diagnostics and Cancer Biomarkers
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Hung Huynh; Huai-Xiang Hao; Stephen L. Chan; David Chen; Richard Ong; Khee Chee Soo; Panisa Pochanard; David Yang; David Ruddy; Manway Liu; Adnan Derti; Marissa N. Balak; Michael R. Palmer; Yan Wang; Benjamin H. Lee; Dalila Sellami; Andrew X. Zhu; Robert Schlegel; Alan Huang
Models and Technologies
RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Naveen K. Tangudu; Vinod K. Verma; Tristan D. Clemons; Syed S. Beevi; Trevor Hay; Ganesh Mahidhara; Meera Raja; Rekha A. Nair; Liza E. Alexander; Anant B. Patel; Jedy Jose; Nicole M. Smith; Bogdan Zdyrko; Anne Bourdoncle; Igor Luzinov; K. Swaminathan Iyer; Alan R. Clarke; Lekha Dinesh Kumar
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds